• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dense Array of Spikes on HIV-1 Virion Particles.HIV-1病毒粒子上的密集刺突阵列
J Virol. 2017 Jun 26;91(14). doi: 10.1128/JVI.00415-17. Print 2017 Jul 15.
2
Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.纯化的化学交联HIV-1刺突的免疫原性展示
J Virol. 2015 Jul;89(13):6725-45. doi: 10.1128/JVI.03738-14. Epub 2015 Apr 15.
3
Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.HIV-1包膜三聚体的功能稳定性影响其顶端对广泛中和抗体的可及性。
J Virol. 2017 Nov 30;91(24). doi: 10.1128/JVI.01216-17. Print 2017 Dec 15.
4
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.小鼠对裂解的可溶性HIV-1包膜三聚体的抗体反应在特异性上受到高度限制。
J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.
5
Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles.鉴定感染性病毒颗粒上的人类免疫缺陷病毒(HIV-1)包膜糖蛋白构象状态。
J Virol. 2023 Mar 30;97(3):e0185722. doi: 10.1128/jvi.01857-22. Epub 2023 Feb 23.
6
Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.流式细胞术分析感染细胞和病毒表面 HIV-1 包膜蛋白构象:Nef、CD4 和 SERINC5 的作用。
J Virol. 2020 Feb 28;94(6). doi: 10.1128/JVI.01783-19.
7
Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions.人类免疫缺陷病毒 1 包膜糖蛋白的双重运输途径调节未切割寡聚体从病毒粒子中的选择性排除。
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01369-20.
8
Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.生成表达不同 HIV-1 糖蛋白的 HIV-1 病毒样颗粒。
Vaccine. 2011 Jul 12;29(31):4903-12. doi: 10.1016/j.vaccine.2011.05.005. Epub 2011 May 17.
9
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.将高水平的嵌合型人类免疫缺陷病毒包膜糖蛋白整合到病毒样颗粒中。
J Virol. 2007 Oct;81(20):10869-78. doi: 10.1128/JVI.00542-07. Epub 2007 Aug 1.
10
Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.未切割与成熟人免疫缺陷病毒膜包膜糖蛋白三聚体的比较。
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00277-18. Print 2018 Jun 15.

引用本文的文献

1
Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice.包含逆转录病毒蛋白酶可增强针对HIV-1或SARS-CoV-2的形成病毒样颗粒的mRNA疫苗在小鼠中的免疫原性。
Sci Transl Med. 2025 Apr 30;17(796):eadt9576. doi: 10.1126/scitranslmed.adt9576.
2
Analysis of Factors That Regulate HIV-1 Fusion in Reverse.HIV-1逆转融合调控因素分析
Viruses. 2025 Mar 26;17(4):472. doi: 10.3390/v17040472.
3
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.人类免疫缺陷病毒1型疫苗研究的进展与挑战:全面综述
Vaccines (Basel). 2025 Jan 31;13(2):148. doi: 10.3390/vaccines13020148.
4
Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.可诱导细胞系产生含有以预触发构象稳定化的包膜糖蛋白的复制缺陷型人类免疫缺陷病毒颗粒。
J Virol. 2024 Dec 17;98(12):e0172024. doi: 10.1128/jvi.01720-24. Epub 2024 Nov 7.
5
Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody.表位结合后产生非双层脂质纳米环境可增强中和 HIV-1 MPER 抗体。
ACS Appl Mater Interfaces. 2024 Nov 6;16(44):59934-59948. doi: 10.1021/acsami.4c13353. Epub 2024 Oct 24.
6
Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.展示能引发2级中和抗体的HIV-1包膜糖蛋白的双组分纳米颗粒疫苗的研发
Vaccines (Basel). 2024 Sep 18;12(9):1063. doi: 10.3390/vaccines12091063.
7
Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.中和威胁:利用抗HIV-1的广谱中和抗体进行治疗和预防。
Microb Cell. 2024 Jul 3;11:207-220. doi: 10.15698/mic2024.07.826. eCollection 2024.
8
Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.用于预防HIV的编码蛋白质和病毒样颗粒的核酸疫苗。
Vaccines (Basel). 2024 Mar 12;12(3):298. doi: 10.3390/vaccines12030298.
9
Purification Method of Extracellular Vesicles Derived from Human T-Cell Leukemia Virus Type 1-Infected Cells without Virions.来源于人 T 细胞白血病病毒 1 感染细胞的细胞外囊泡的无病毒粒子的纯化方法。
Viruses. 2024 Feb 4;16(2):249. doi: 10.3390/v16020249.
10
The Antiviral Activity of the Lectin Griffithsin against SARS-CoV-2 Is Enhanced by the Presence of Structural Proteins.凝集素 Griffithsin 对 SARS-CoV-2 的抗病毒活性可被结构蛋白增强。
Viruses. 2023 Dec 18;15(12):2452. doi: 10.3390/v15122452.

本文引用的文献

1
Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles.展示具有自组装纳米颗粒的类天然三聚体 HIV-1 抗原。
Nat Commun. 2016 Jun 28;7:12041. doi: 10.1038/ncomms12041.
2
High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.合成脂质体纳米颗粒上排列有序的高密度HIV-1刺突阵列可有效激活B细胞。
Cell Rep. 2016 May 31;15(9):1986-99. doi: 10.1016/j.celrep.2016.04.078. Epub 2016 May 19.
3
Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry.光学捕获病毒测量法揭示HIV-1病毒体上感染性与Gp120密度之间的定量相关性。
J Biol Chem. 2016 Jun 17;291(25):13088-97. doi: 10.1074/jbc.M116.729210. Epub 2016 Apr 25.
4
Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer.天然、完全糖基化、裂解的HIV-1包膜三聚体的冷冻电镜结构
Science. 2016 Mar 4;351(6277):1043-8. doi: 10.1126/science.aad2450.
5
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.诱导广泛中和抗体的HIV-1包膜三聚体设计与免疫策略
Trends Immunol. 2016 Mar;37(3):221-232. doi: 10.1016/j.it.2016.01.007. Epub 2016 Feb 9.
6
Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines.HIV-1包膜糖蛋白胞质尾修饰对病毒样颗粒疫苗免疫原性的影响
Virology. 2016 Feb;489:141-50. doi: 10.1016/j.virol.2015.09.015. Epub 2016 Jan 4.
7
MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins.MARCH8 通过减少病毒包膜糖蛋白的病毒粒子整合来抑制 HIV-1 感染。
Nat Med. 2015 Dec;21(12):1502-7. doi: 10.1038/nm.3956. Epub 2015 Nov 2.
8
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.在铁蛋白纳米颗粒上呈现类似天然的HIV-1包膜三聚体可提高其免疫原性。
Retrovirology. 2015 Sep 26;12:82. doi: 10.1186/s12977-015-0210-4.
9
IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.干扰素诱导跨膜蛋白(IFITM)通过拮抗包膜糖蛋白来限制HIV-1感染。
Cell Rep. 2015 Oct 6;13(1):145-156. doi: 10.1016/j.celrep.2015.08.055. Epub 2015 Sep 17.
10
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.小鼠对裂解的可溶性HIV-1包膜三聚体的抗体反应在特异性上受到高度限制。
J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

HIV-1病毒粒子上的密集刺突阵列

Dense Array of Spikes on HIV-1 Virion Particles.

作者信息

Stano Armando, Leaman Daniel P, Kim Arthur S, Zhang Lei, Autin Ludovic, Ingale Jidnyasa, Gift Syna K, Truong Jared, Wyatt Richard T, Olson Arthur J, Zwick Michael B

机构信息

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.

出版信息

J Virol. 2017 Jun 26;91(14). doi: 10.1128/JVI.00415-17. Print 2017 Jul 15.

DOI:10.1128/JVI.00415-17
PMID:28446665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5487557/
Abstract

HIV-1 is rare among viruses for having a low number of envelope glycoprotein (Env) spikes per virion, i.e., ∼7 to 14. This exceptional feature has been associated with avoidance of humoral immunity, i.e., B cell activation and antibody neutralization. Virus-like particles (VLPs) with increased density of Env are being pursued for vaccine development; however, these typically require protein engineering that alters Env structure. Here, we used instead a strategy that targets the producer cell. We employed fluorescence-activated cell sorting (FACS) to sort for cells that are recognized by trimer cross-reactive broadly neutralizing antibody (bnAb) and not by nonneutralizing antibodies. Following multiple iterations of FACS, cells and progeny virions were shown to display higher levels of antigenically correct Env in a manner that correlated between cells and cognate virions ( = 0.027). High-Env VLPs, or hVLPs, were shown to be monodisperse and to display more than a 10-fold increase in spikes per particle by electron microscopy (average, 127 spikes; range, 90 to 214 spikes). Sequencing revealed a partial truncation in the C-terminal tail of Env that had emerged in the sort; however, iterative rounds of "cell factory" selection were required for the high-Env phenotype. hVLPs showed greater infectivity than standard pseudovirions but largely similar neutralization sensitivity. Importantly, hVLPs also showed superior activation of Env-specific B cells. Hence, high-Env HIV-1 virions, obtained through selection of producer cells, represent an adaptable platform for vaccine design and should aid in the study of native Env. The paucity of spikes on HIV is a unique feature that has been associated with evasion of the immune system, while increasing spike density has been a goal of vaccine design. Increasing the density of Env by modifying it in various ways has met with limited success. Here, we focused instead on the producer cell. Cells that stably express HIV spikes were screened on the basis of high binding by bnAbs and low binding by nonneutralizing antibodies. Levels of spikes on cells correlated well with those on progeny virions. Importantly, high-Env virus-like particles (hVLPs) were produced with a manifest array of well-defined spikes, and these were shown to be superior in activating desirable B cells. Our study describes HIV particles that are densely coated with functional spikes, which should facilitate the study of HIV spikes and their development as immunogens.

摘要

在病毒中,HIV-1较为罕见,其每个病毒体的包膜糖蛋白(Env)刺突数量较少,即约7至14个。这一特殊特征与逃避体液免疫相关,即B细胞活化和抗体中和。为了疫苗开发,人们正在研究Env密度增加的病毒样颗粒(VLP);然而,这些通常需要通过蛋白质工程来改变Env结构。在此,我们采用了一种针对生产细胞的策略。我们利用荧光激活细胞分选技术(FACS)对能被三聚体交叉反应性广泛中和抗体(bnAb)识别但不能被非中和抗体识别的细胞进行分选。经过多次FACS迭代后,细胞和子代病毒体显示出以细胞与其同源病毒体之间相关的方式呈现出更高水平的抗原正确的Env(r = 0.027)。高Env VLP,即hVLP,经电子显微镜显示为单分散的,且每个颗粒的刺突增加了10倍以上(平均127个刺突;范围为90至214个刺突)。测序显示在分选过程中Env的C末端尾巴出现了部分截断;然而,高Env表型需要进行多轮“细胞工厂”选择。hVLP显示出比标准假病毒体更高的感染性,但中和敏感性大致相似。重要的是,hVLP在激活Env特异性B细胞方面也表现出优越性。因此,通过选择生产细胞获得的高Env HIV-1病毒体代表了一种适用于疫苗设计的平台,应有助于对天然Env的研究。HIV上刺突稀少是与逃避免疫系统相关的一个独特特征,而增加刺突密度一直是疫苗设计的目标。通过各种方式修饰Env来增加其密度取得的成功有限。在此,我们转而关注生产细胞。基于bnAb的高结合和非中和抗体的低结合,对稳定表达HIV刺突的细胞进行筛选。细胞上的刺突水平与子代病毒体上的刺突水平密切相关。重要的是,产生的高Env病毒样颗粒(hVLP)具有明显排列的明确刺突,并且这些在激活所需B细胞方面表现出优越性。我们的研究描述了密集包裹有功能性刺突的HIV颗粒,这应有助于对HIV刺突及其作为免疫原的开发进行研究。